SEC Form 4 · accession 0001477932-16-011031
Citius Pharmaceuticals, Inc. · CTXR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard Safir
Director
Period of report
Jun 23, 2016
Accepted (ET)
Jun 27, 2016 · 5:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001506251
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2 | $0.80 | Jun 23, 2016 | A | 200,000 | A | — | Jun 23, 2026 | Common Stock | 200,000 | 200,000 | D |
| Options to Purchase Common StockF1 | $0.001 | holding | — | — | — | — | — | Common Stock | — | 181,056 | D |
Explanation of responses
- F1On April 11, 2014 the Reporting Person was granted a ten-year option to purchase 100,000 shares of LMB common stock at an exercise price of $0.001 per share. The option vests in 1/3 increments over a three year period commencing on the first anniversary of the date of the grant, or April 11, 2015. On March 30, 2015 the Issuer entered into that certain Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Citius LMB Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Issuer and Leonard-Meron Biosciences, Inc., a Delaware corporation ("LMB"). Pursuant to the Merger Agreement, the option was converted into an option to purchase 181,056 shares of the Issuer's common stock at a per share exercise price of $0.001. The Option vests in 1/3 increments over a three year period with the first installment vesting on April 11, 2015.
- F2The options vest in full on the first anniversary of the date of grant.